KLRK1 and cancer: Strategies that target CD24 expression or function in cancer cells could enhance NKG2D-mediated immune responses, potentially overcoming immune evasion mechanisms and improving the efficacy of treatments designed to activate NK and T cells against cancer (15, 167).